Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). This suppresses the formation of new blood vessels required for tumour growth and metastasis.
Recommended for:
Administered intravenously by infusion in a clinical setting. Dosage is based on cancer type, patient’s weight, and chemotherapy protocol.
Contraindications:
Side effects: